Redhill Biopharma Ltd. ADR [RDHL] stock is trading at $0.53, down -3.60%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The RDHL shares have gain 14.97% over the last week, with a monthly amount drifted -6.23%, and not seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
On 2, April 2024, RedHill Biopharma Announces $1.25 Million Registered Direct Offering at a Premium to Market Price. In a post published today on Yahoo Finance, RedHill Biopharma Ltd. (Nasdaq: RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company, today announced that it has entered into definitive agreements with private investors for the purchase and sale, at a premium, of 2,144,487 of the Company’s American Depositary Shares (“ADSs”), each ADS representing four hundred (400) ordinary shares, par value NIS 0.01 per share, of the Company, and warrants to purchase up to an aggregate of 2,144,487ADSs, at a purchase price of $0.58289 per ADS and accompanying warrant, in a registered direct offering. The price per ADS and accompanying warrant represents a premium of 10% over $0.5299, the closing price of the ADSs as reported by the Nasdaq Capital Market on March 28, 2024. The warrants will have an exercise price of $0.75 per ADS, will be immediately exercisable upon issuance and have a term of five years following the issuance date. The closing of the offering is expected to occur on or about April 3, 2024, subject to the satisfaction of customary closing conditions.
From an analyst’s perspective:
Redhill Biopharma Ltd. ADR [NASDAQ: RDHL] stock has seen the most recent analyst activity on August 31, 2021, when Cantor Fitzgerald initiated its Overweight rating and assigned the stock a price target of $22. Previously, H.C. Wainwright started tracking the stock with Buy rating on May 18, 2021, and set its price target to $23. On September 11, 2020, BTIG Research initiated with a Buy rating. WBB Securities upgraded its rating to a Strong Buy. WBB Securities upgraded its rating to a Buy. Nomura started tracking with a Buy rating for this stock on January 26, 2018, and assigned it a price target of $18. In a note dated October 06, 2017, Seaport Global Securities initiated an Buy rating and provided a target price of $19 on this stock.
Redhill Biopharma Ltd. ADR [RDHL] stock has fluctuated between $0.26 and $4.24 over the past year. Redhill Biopharma Ltd. ADR [NASDAQ: RDHL] shares were valued at $0.53 at the most recent close of the market.
Analyzing the RDHL fundamentals
Redhill Biopharma Ltd. ADR [NASDAQ:RDHL] reported sales of 35.52M for the trailing twelve months, which represents a drop of -90.21%. Gross Profit Margin for this corporation currently stands at 0.39% with Operating Profit Margin at 2.0%, Pretax Profit Margin comes in at 2.6%, and Net Profit Margin reading is 2.94%. To continue investigating profitability, this company’s Return on Assets is posted at 1.53, Equity is -3.74 and Total Capital is 5.3. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.66.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 0.5150 points at the first support level, and at 0.5000 for the second support level. However, for the 1st resistance point, the stock is sitting at 0.5400, and for the 2nd resistance point, it is at 0.5500.
Redhill Biopharma Ltd. ADR [RDHL] reported earnings per share of -$0.2 for its fiscal quarter that ended on 6/29/2022. Based on the Wall Street analysts’ estimates, the company was expected to report earnings of -$0.03/share, meaning a difference of -$0.17 and a surprise factor of -566.70%. By comparison, the stated earnings for the previous quarter ended on 3/30/2022 were -$0.3 per share as compared to estimates of -$0.23 per share, a difference of -$0.07 representing a surprise of -30.40%.
Ratios To Look Out For
For context, Redhill Biopharma Ltd. ADR’s Current Ratio is 0.96. Further, the Quick Ratio stands at 0.78, while the Cash Ratio is 0.25. Considering the valuation of this stock, the price to sales ratio is 0.44, the price to book ratio is 0.60.
